- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
CAR-T Cell-Therapies in Development, Update 2022
CAR-T cell-therapies are commonly indicated as „transformative“ therapies referring to the huge expectations associated with them since their market approval in 2017 (USA) and 2018 (Europe). Due to the hope, but also the enormous prices a horizon scanning (HS) document was first published in 2020 to support budget planning in hospitals. In 2020 13 CAR-T cell-therapies in advanced stages were identified. Of these, in addition to Yescarta® and Kymriah®, that were already approved at that time, three further therapies have since been approved by the European Medicines Agency (EMA) between 8/ 2020 and 03/2022: Tecartus® (2020), Abcema® (2021) and Breyanzi® (2022).
This HS document updates the earlier report by surveying the status of the ten therapies already described in 2020 and adding additional therapies that have since then reached a later phase of clinical testing. Within the next year 2023 one new CAR-T cell-Therapy for multiple myeloma will eventually be approved, but further development can be expected with the extension of the approved CAR-T cell-therapies towards earlier lines of therapy and new indications.
Publication: Policy Brief No. 6a, 1. Update: https://eprints.aihta.at/1368
Contakt: Ozren Sehic
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our seven new HSO Fact Sheets.
Fact Sheet No. 79 (March 2022)
Tebentafusp (Kimmtrak®) bei Uveal melanoma
Fact Sheet No. 80 (March 2022)
Relugolix (Orgovyx®) bei Prostate Cancer
Fact Sheet No. 81 (March 2022)
Nivolumab (Opdivo®) bei MIUC
Fact Sheet No. 82 (March 2022)
Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC
Fact Sheet No. 83 (March 2022)
Nivolumab (Opdivo®) + chemotherapy bei OSCC
Fact Sheet No. 84 (March 2022)
Abemaciclib (Verzenios®) bei early breast cancer
Fact Sheet No. 85 (March 2022)
Enfortumab vedotin (Padcev®) Urothelial cancer
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Neue Evidenzanalyse zum Brustkrebs-Screening in Deutschland auch für Österreich von Relevanz
- Nicht-medikamentöse Verfahren bei fortgeschrittenem Lymphödem
- Komplementärmedizin bei Krebs: Empfehlungen der neuen S3-Leitlinie
- Tomosynthese zur Mammographie
- Fernüberwachung von Patient*innen mit kardiovaskulären implantierbaren elektronischen Geräten
- Termine
- Themen-Vorschau
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v20 February/ March 2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our two new HSO Fact Sheets.
Fact Sheet No. 77 (February 2022)
Lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory DLBCL
Fact Sheet No. 78 (February 2022)
Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Disruptive Technologien im Gesundheitswesen
- Evidenzlücken beim Markteintritt: mögliche Lösungen
- Fehlender Nutzenbeleg zu Unterdruck-Wundtherapie mit Einweggeräten
- Knochenwachstumsstimulatoren für die Behandlung von Erwachsenen mit Knochenkrankheiten oder –verletzungen
- Medizinisches Cannabis bei Spastik und chronischen Schmerzen
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our five new HSO Fact Sheets.
Fact Sheet No. 72 (January 2022)
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer
Fact Sheet No. 73 (January 2022)
Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 74 (January 2022)
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)
Fact Sheet Nr. 75 (January 2022)
Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 76 (January 2022)
Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Messung des Gesundheitszustands aus Patient*innensicht zur Verbesserung von Behandlungsentscheidungen
- Die ökonomische und gesellschaftliche Dimension elterlicher psychischer Erkrankungen
- Strategien zum Management von Labornachfragen
- Haut-Substitute bei chronischen Wunden
- Ezetimib zur Behandlung von Fettstoffwechselerkrankungen
- Termine
- Themen-Vorschau
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v19 December 2021/January 2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Announcement
>=12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies
Since 2017, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved three drugs for the treatment of SMA. Results of the pivotal trials showed clinically meaningful improvements (MCID) in motor skills in SMA type 1 (especially those with early treatment initiation and ?2 SMN2 copies), as well as a stabilisation of health status in SMA type 2 to 4 patients. In SMA type 1 patients, while motor skills improved, no changes (sometimes even a deterioration) in the need for ventilation and nutritional support could be observed. The present report aims to synthesize the evidence on mid- and long-term (? 12 months) follow-up of the approved drugs as monotherapies or as combination therapies.
Twenty-two observational studies were included for analysing mid- and long-term outcomes. The included studies reported on 840 SMA patients, of which 289 SMA type 1 patients and 521 SMA type 2 to 4 patients were treated with nusinersen, only 12 SMA type 1 patients with onasemnogene abeparvovec and 18 SMA type 1 patients received a combination therapy.
Publication: Policy Brief No. 001, 1. Update: https://eprints.aihta.at/1352
Contact: Judit Erdös, Claudia Wild
